FEB 13 TOTAL TO

S. Department of Commerce tent and Trademark Office

Atty. Docket: 2002941-0053

In re Application No. 09/289,321

COPY OF PAPERS

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant: Bachovchin

Filing Date: April 9, 1999 Group:

1653 RECEIV**∉**D

FEB 2 0 2002

U. S. PATENT DOCUMENTS

U. S. PATEN	NT DOCUMENTS			TECH	CENTER 1600/2
Examiner's Initials	U.S. Patent No.	Applicant	Issue Date	Class	Subclass
Initials	* 4,318,904	Shaw et al.	March 9, 1982	424	177
	* 4,443,609	Oude Alink et al.	April 17, 1984	548	111
	* 4,499,082	Shenvi et al.	February 12, 1985	514	2
	* 4,582,821	Kettner et al.	April 15, 1986	514	18
	* 4,636,492	Kettner et al.	January 13, 1987	514	18
	* 4,644,055	Kettner et al.	February 17, 1987	530	330
	* 4,652,552	Kettner et al.	March 24, 1987	514	18
	* 4,935,493	Bachovchin et al.	June 19, 1990	530	331
	* 4,963,655	Kinder et al.	October 16, 1990	530	331
	* 5,093,477/	Mölling et al.	March 3, 1992	530	328
	* 5,187,157	Kettner et al.	February 16, 1993	514	18
	* 5,215,926	Etchells, III et al.	June 1, 1993	436	501
	* 5,242,904	Kettner et al.	September 7, 1993	514	18
	*,5,250,720	Kettner et al.	October 5, 1993	558	288
	* 5,288,707	Metternich	February 22, 1994	514	19
	* 5,296,604	Hanko et al.	March 22, 1994	546	169
	* 5,329,028	Ashkenazi et al.	July 12, 1994	548	548
	* 5,378,624	Berenson et al.	January 3, 1995	435	239
	* 5,384,410	Kettner et al.	January 24, 1995	548	405
1	* 5,444,049	de Nanteuil et al.	August 22, 1995	514	18
	* 5,462,928	Bachovchin et al.	October 31, 1995	514	19

145	.	tment of Commerce Trademark Office	Atty. Docket: 2002941-0053	In re App 09/289,32	lication No.
INFORMATION DISCLOSURE STATEMENT			Applicant: Bachovchin		
(Use several sh	neets if necessary)		Filing Date: April 9, 1999	Group: 1653	
* 5,	,506,130	Peterson et al.	April 9, 1996/	435	240.1
* 5,	,527,923	Klinger et al.	June 18, 1996	548	570
* 5,	543,396	Powers et al.	August 6, 1996	514	19
* 5,	,554,728	Basava et al.	September 10, 1996	530	327
* 5,	,635,386	Palsson et al.	June 3, 1997	435	372
* 5,	,635,387	Fei et al.	June 3, 1997	435	378
* 5,	,646,043	Emerson et al.	July 8, 1997	435	373

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Document No.	Country	Date	Translation	
				Yes	No
	DD158109	Germany	29 December 1982		X
	DD270382A1	Germany	26 July 1989		X
	DD296075A5	Germany	21 November 1991		X
	EP 0356223A2	Europe	28 February 1990	X	
	EP 0371467A2	Europe	6 June 1990		X
	* EP 0420913B1	Europe	15 November 1995		
	* EP 0471651A2	Europe	19 February 1992		
	EP 0481311A2	Europe	22 April 1992		X
	EP 0615978A1	Europe	21 September 1994		X
	EP 0688788A1	Europe	27 December 1995		X
	* WO 89/03223	PCT	20 April 1989		
	* WO 91/16339	PCT	31 October 1991		······································
·	* WO 91/17767	PCT	28 November 1991		-

	rtment of Commerce Trademark Office	Atty. Docket: 2002941-0053	In re Application No. 09/289,321
INFORMATION DISCLOSURE STATEMENT	FEB 13 MAR ST	Applicant: Bachovchii	1
(Use several sheets if necessary)	PROPERTY & TRADE	Filing Date: April 9, 1999	Group: 1653
* WO 92/12140	PCT	23 July 1992	
* WO 92/17490	PCT	15 October 1992	
* WO 93/02057	PCT	4 February 1993	
* WQ 93/05011	PCT	18 March 1993	
* WO 93,08259	PCT	29 April 1993	
* WO 93/10127	PCT	27 May 1993	
* WO 93/16102	PCT	19 August 1993	
* WO 94/03055	RCT /	17 February 1994	
* WO 94/09132	PCT	28 April 1994	
* WO 94/20526	PCT	15 September 1994	
* WO 94/25873	PCT	10 November 1994	
* WO 94/28915	PCT	22 December 1994	
* WO 94/29335	PCT	22 December 1994	
* WO95/11689	PCT	4 May 1995	
WO95/15309	PCT	6 June 1995	X
* WO 95/15309	PCT	8 June 1995	
* WO 95/12618	PCT	11 May 1995	
* WO 95/29190	PCT	2 November 1995	
* WO 95/29 6 91	PCT	9 November 1995	
* WO 95/34538	PCT	21 December 1995	
* WO 96/40858	PCT	19 December 1996	
* WO 96/40263	PCT	19 December 1996	
WO 98/00439	PCT	8 January 1998	X
WO 98/50046	PCT	12 November 1998	X
WO 98/50066	PCT	12 November 1998	X

In re Application No. U.S. Department of Commerce Atty. Docket: Form PTO-1449 2002941-0053 09/289,321 Patent and Trademark Office (REV. 8-83) **INFORMATION** Applicant: Bachovchin DISCLOSURE STATEMENT FEB 13 2002 Group: Filing Date: (Use several sheets if necessar) 16 RECEIVEP April 9, 1999 8 April 1999 WO 99/16864 **PCT** TECH CENTER 1600 2900 OTHER DOCUMENTS Examiner's (Including Author, Title, Date, Pertinent Pages, Etg. Initials Aguila, H.L., et al., From Stem Cells To Lymphocytes: Biology and Transplantation", Immun. Rev., 157:13-4Q, (1997) Ansorge, et al., "CD26/Dipeptidyl Peptidase IV in Lymphocyte Growth Regulation", 127-140. * Austin, D.J., et al., "Proximity Versus Allostery; The Role of Regulated Protein Dimerization in Biology", Chemistry & Biology, 1:131-136, (1994) * Bachovchin, W.W., et al., "Inhibition Of IGA 1 Proteinases From Neisseria Gonorrhoeae And Hemophilus Influenzae By Peptide Prolyl Boronic Acids", J. Biol. Chem., 265:3738-3743 (1990). * Bailey, P.D., "An Introduction To Peptide Chemistry", Wiley Publishers, 1-81, (1990) * Barton, R.W.J., et al., "Binding Of The T Cell Activation Monocional Antibody Tal To Dipeptidyl Peptidase IV", J. Leukocyte Biology, 48:291-296 (1990). Baugh, R., et al., "Role and Potential Therapeutic Value of Proteinase Inhibitors in Tissue Destruction", Proteinases and Tumor Invation, 165:157-180 (1980). * Blumenstein, et al., "Synthetic Non-Peptide Inhibitors of HIV Protease" Biochemical and Biophysical Research Communications 163(2): 980-87, 1989. * Bodanszky, M., "Principles Of Peptide Synthesis", Springer-Verlag, 16: (1984) * Bodanszky, M., "The Practice Of Peptide Synthesis", Springer-Verlag, 21: (1984) * Bodanzky, M./ "Peptide Chemistry, A Practical Textbook", Springer-Verlag, (1988) 1-9. * Boros, L.G., et al., "Fluoroolefin Peptide Isosteres-Tools For Controlling Peptide Conformations", Tetrahedron Letters, 35:6033-6036., (1994) * Brady, L., and Dodson, G., "Reflections On A Peptide", Nature, 368:692-693, (1994) * Brander et al., "Heterogeneous T Cell Responses to β-Lactam-Modified Self-Structures Are Observed in Penicillin-Allergic Individuals" J. Immunol. 155 (5):2670-2678 (1995). * Brenchley, et al., "Towards Defining Antigens in Human Membranous Nephropathy" Nephrology, Dialysis, Transplantation 7 Supp. 1: 21-24, (1992). Bristol, L.A., et al., "Characterization Of A Novel Rat Thymocyte Costimulating Antigen By The Monoclonal Antibody 1.3", J. Immunol., 148:332-338 (1992). * Bristol, L.A., et al., "Thymocyte Costimulating Antigen is CD26 (Dipeptidyl-Peptidase IV), Co-stimulation Of Granulocyte, Macrophage, T Lineage Cell Proliferation Via CD26," J. Immunol., 149:367-372 (1992). Bristol, et al., "Inhibition of CD26 Enzyme Activity with Pro-boropro Stimulates Rat Granulocyte/Macrophage Colony Formation and Thymocyte Proliferation In Vitro", Blood, 85(12): 3602-3609, 1995.

In re Application No. Atty. Docket: U.S. Department of Commerce Form PTO-1449 FEB 2 0 2002
GroupH CENTER 1600/2900 09/289,321 Patent and Trademark Office 2002941-0053 (REV. 8-83) **INFORMATION** Applicant: Bachovchin DISCLOSURE STATEMENT Filing Date: (Use several sheets if necessary April 9, 1999 * Bungy, et al., Mapping of F cell Epitopes of the Major Fraction of Rye Grass Using Peripheral Blood Mononuclear Cells From Atopics and Non-Atopics. II. Isoallergen Clone 5A of Lolium Perenne Group I (Lol p I). Eur/J. Immunol. 24 (9):2098-2103 (1994). * Chan, et al., "Archives of Ophthalmology 113 (5):597-600 (1995). * Chazenblak, et al., "Human Organ-Specific Autoimmune Disease", Molecular Cloning and Expression of an Autoantibody Gene Repertoire For a Major Autoantigen Reveals an Antigenic Immunodominant Region and Restricted Immunoglobulin Gene Usage in the Target Organ, J. Clinical Investigation 92 (1):62-74 (1993). * Colowick, S., et al., "Methods In Enzymology", Pp. 220-225. * Cordes, E., et al., "Transition States For Hydrolysis Of Acetals, Ketals Glycosides, And Glycosylamines", Chapter 11, Pp. 429-465 * Coutts, et al., "Structure-Activity Relationships of Boronic Acid Inhibitors of Dipeptidyl Peptidase IV. 1. Variation of the P₂ Position of X_{aa} -boroPro Dipeptides", J. Med. Chem., 39: 2087-94, 1996. * Dang, N.H., et al., "Cell Surface Modulation of CD26 By Anti-1F7 Monocional Antibody: Analysis Of Surface Expression And Human T Cell Activation", J. Immunol., 145:3963-3971 (1990).* Darcy, et al., "Protection of Mice and Nude Rats Against Toxolasmosis by A Multiple Antigenic Peptide Construction Derived From Toxoplasma Gondii P30 Antigen", J. Immunol. **149** (11):3636-3641 (1992). * Darmoul, D/, et al. "Dipeptidyl Peptidase IV (CD26) Gene Expression in Enterocyte-like Colon Cancer Cell Lines HT-29 And Caco-2; Cloning Of The Complete Human Coding Sequence And Changes of Dipeptidyl Peptidase IV mRNA Levels During Cell Differentiation," J. Biological Chemistry, 267:220-2208 (1992). * Daw, et al., "Glutamic Acid Decarboxylase Autoantibodies in Stiff-Man Syndrome and Insulin-Dependent Diabetes Mellitus Exhibit Similarities and Differences in Epitope Recognition", J. Immunol. 156 (2): 818-825 (1996). * De Caestecker, M.P., et al., "The Detection Of Intercytoplasmic Interleukin 1 (Alpha) Expression In Human Monocytes Using Two Colour Immunofluorescence Flow Cytometry", J. Immunol. Methods 154:11-20 (1992). * Demuth, H.U., et al. "Design Of (Omega-N-(O-Acyl)Hydroxy Amid) Aminodicarboxylic Acid Pyrrolidides As Potent Inhibitors Of Proline-Specific Peptidases", FEBS Lett., 320:23-27, (1993) * Dudler, et al., "Carbohydrate-Dependent, HLA Class II-Restricted, Human T Cell Response to the Bee Venom Allergen Phospholipase A2 in Allergic Patients", Eur. J. Immunol. 25 (2):538-542 (1995). * Duke-Cohan, J.S., et al., "Targeting Of An Activated T-Cell Subset Using A Bispecific Antibody-Toxin Conjugated Directed Against CD4 AND CD26", Blood, 82:2224-2234.,

(1993).

U.S. Department of Commerce Patent and Trademark Office

Atty. Docket: 2002941-0053 In re Application No. 09/289,321

INFORMATION DISCLOSURE STATEMENT



Applicant: Bachovchip

(Use seve	ral sheets if necessary)	Filing Date:	Group:			
	BY FAIR & TRANSPIRE	April 9, 1999	1653			
	Dupont, B., "Immunology Of Hematopoietic S	tem Cell Transplantation	: A Brief Review Of			
	Its History", Immun. Rev., 157:5-12. (1997)					
	* Ebenbichler, C., et al., "Structure-function Relationships Of The HIV-1 Envelope V3 Loop					
	Tropism Determinant: Evidence For Two Distinct Conformations", Aids 7:639-46 (1993).					
	* El Far, et al., "Antigens Associated with N- and L-Type Calcium Channels in Lambert -					
	Eaton Myasthenic Syndrome", J. Neurochemistry, 64 (4): 1696-1702 (1995). * Fauci, A.S., "The Human Immunodeficiency Virus: Infectivity And Mechanisms Of					
	Pathogenesis", Science, 239:617:722 (1988).					
	* Fleisher, B., et al., "Triggering of Cytotoxic"					
	Pathway is Dependent On the Expression Of T	The T Cell Receptor/CD3	Complex", J.			
	Immuno,,. 141:1103-1107.	\				
	* Flentke, G.R., et al., "Inhibition of Dipeptid					
	Boropro Dipetides And Use Of These Inhibitor		Of DP-IV IN I-Cell			
	Function", Proc. Natl. Acad. Sof. USA, 88:155		·			
	* Freeman, et al., "T and B Cell Reactivity to	, -	oimmune Addison's			
	Disease" Clinical & Experimental Immunology		Dadiandaida			
	Goodman, et al., "Cellular/Immunity to Cartila					
	Rheumatoid Arthritis and Non-Arthritic Control 46, 1996.					
	* Goodman, M., and Chorev, M., "On The Cor		l Retro-Peptide			
	Structures", Accounts of Chemical Research, 1					
	Goodstone, et al., "Cellular Immunity to Cartil	age Aggrecan Core Prote	ein in Patients with			
	Rheumatoid Arthrifis and Non-Arthritic Contro	ols"Annals Of The Rheun	natic Diseases			
	55(1):40-46 (1996).					
	* Guichard, G., et al. "Partially Modified Retro					
	Ligands For The Human Class I Histocompatil	bility Molecule HLA-A2	, J. Mea. Chem.,			
	39 :2030-2039,/(1996)	CEL DD HI (CDOC) I 1 '	1 '4 X7.1 D D			
	* Günther, U.L., et al., "Solution Structures Of					
	Determined By NMR Spectroscopy", Magneti					
	Gutheil, W.G., et al., "Separation Of L-PRO-D					
	And Kinetic Analysis Of Their Inhibition Of I					
	The Analysis Of Slow, Tight-Binding Inhibition					
	* Hall, et al., "Immunogenetics of Dermatitis I 10 (3):240-245 (1991).	Herpenformis, Seminar.	s in Dermatology,			
	* Hart, et al., "Design of Experimental Synthe					
	1 and HTLV-1 Retroviral Infections", Pharma					
	* Hegen, M., et al. "Enzymatic Activity Of CL					
	For Its Signalling Function In T Cells", Immur	obiology, 189 :483-493,	(1993)			
	* Hegen, M., et al. "Function Of Dipeptidylpe		3) In Transfected			
	Human T Cells", Cell Immunol., 146:249-260,	(1993)				

U.S. Department of Commerce Patent and Trademark Office

Atty. Docket: 2002941-0053 In re Application No. 09/289,321

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)



Applicant: Bachovchin

Filing Date:

(U.	se several sheets if necessary) April 9, 1999 1653
	se several sheets if necessary) April 9, 1999 1653 Group.** CENTER 1600
	* Hegen, M., et al., "The T Cell Triggering Molecule Tp 103, J. Immunol., 144:2980-2914
	(1990).
	* Heins, J., et al., "Mechanism of Proline-Specific Proteinases: (I) Substrate Specificity of
	Dipeptidyl Peptidase Peptidase IV From Pig Kidney and Proline-Specific Endopeptidase
	From Flavobacterium Meningosepticum", Biochemica Biophysica Acta, 954:161-169 (1988).
	* Ikagawa, et al., "Single Amino and Acid Substitutions on a Japanese Cedar Pollen Allergen
	Cry J-1) Derived Peptide Induced Alterations in Human T Cell Responses and T Cell
	Receptor Antagonism" J. Allergy & Clinical Immunol. 97 (1 Pt 1): 53-64 (1996).
	* James, et al., "Peptide Autoantigenicty of the Small Nuclear Ribonucleoprotein C" Clinical
	& Experimental Rheumatology, 13 (3):299-305 (1995).
	* Jameson, B.A., et al., "A Rationally Designed CD4 Analogue Inhibits Experimental Allergic
	Encephalomyelitis", Nature, 368:744-746, (1994).
	* Janeway, C., et al., "Immunobiology - The Immune System In Health And Disease",
	Current Biology LTD, Chapter 12, pp. 1-35, (1994).
	* Jardetzky, T.S., et al., "Three-Dimensional Structure Of A HumanClass II
	Histocompatibility Molecule Complexed With Superantigen, Nature, 368:711-718 (1994)
	* Jiang, et al., "Inhibition of Human Immunodeficiency Virus Type I Infection in a T-Cell
	Line (CEM) by New Dipeptidyl-Peptidase IV (CD26) Inhibitors", Res Viral, 148: 255-266,
	1997.
	* Jorgensen, J.L., et al., "Molecular Components Of T-Cell Recognition," Annu. Rev.
	Immunol. 10:835-873 (1992).
	* Kalluri, et al., "Indentification of the Alpha 3 Chain of Type IV Collagen as the Common
	Autoantigen in Antibasement Membrane Disease and Goodpasture Syndrome", J. The
	American Society Of Nephrology 6 (4):1178-1185 (1995).
	* Kameoka, J., et al., "Direct Association Of Adenosine Deaminase With A T Cell Activation
	Antigen, CD26 ¹ , Science, 261:466-469, (1993)
	* Kameoka, Jr, et al., "Differential CD26-Mediated Activation Of The CD3 AND CD2
	Pathways After CD6-Depleted Allogeneic Bone Marrow Transplantation", Blood 85:1132-
	1137, (1995)
	* Karges, et al., "Self and Non-Self Antigen in Diabetic Autoimmunity: Molecules and
ļ	Mechanisms", Molecular Aspects Of Medicine 16(2):29-213 (1995).
	* Kelly, T.A., et al., "Immunosuppressive Boronic Acid Dipeptides: Correlation Between
	Conformation And Activity", J. Am. Chem. Soc., 115:12637-12638, (1993)
	* Kelly, T.A., et al., "The Efficient Synthesis And Simple Resolution Of A Proline Boronate
	Ester Suitable For Enzyme Inhibition Studies", Tetrahedron 49:1009-1016 (1993).
	* Kettner, C.A. and Shenvi, A.B., "Peptide Boronic Acid Inhibitors Of Trypsin-Like Proteases Their Proportion And Head As Anticocculorts And Inflammation Inhibitors." Chemical
	Their Preparation And Use As Anticoagulants And Inflammation Inhibitors", Chemical
	Abstracts, (1990), 112:80 (91790c). * Kettner, C.A., et al., "Kinetic Properties Of The Binding Of Alpha-Lytic Protease To
	Peptide Boronic Acids", Biochemistry, 27:7682-7688, (1988).
	replice Botomic Acids, biochemistry, 21./002-7000, (1700).

U.S. Department of Commerce Patent and Trademark Office

Atty. Docket: 2002941-0053 In re Application No. 09/289,321

INFORMATION DISCLOSURE STATEMENT



Applicant: Bachovchin

	(Use several sheets if necessary) * Kinder, D., et al., "Analogues of Carbamy Aspartate as Inhibitors" J. Med. Chem.,					
	(Use several sheets if necessary) April 9, 1999 1653					
	Terrange III I I I I I Cham					
	* Kinder, D., et al., "Analogues of Carbamy Aspartate as Inhibitors" J. Med. Chem.,					
	1. "Detection of Platelet Antigen for Antiplatelet Antibodies in Idiopatine					
	The same Let Class V Mampiry Millipolity Cupies 22-2-3					
	Thrombocytopenic Purpura by Flow Cytometry, Finingen Transport of					
	* Kubota, T., et al., "Diipepidyl peptidase IV (DP IV) Activity In Serum and On * Kubota, T., et al., "Diipepidyl peptidase IV (DP IV) Activity In Serum and On Lymymphocytes Of Mri/Mp-Ipp/lpr Mice Correlates With Disease Onset", Clin. Exp.					
	* Kubota, T., et al., "Involvement Of Dipeptidyl Peptidase IV In An In Vivo Immune					
	* Kuchroo, V.K., et al., "A Single TCR Antagonist repitte in interior and the Encephalomyelitis Mediated By A Diverse T Cell Repertoire", J. Immunol. 153:3326-3336					
	(1994)					
<u> </u>	(1994). * Kuchroo, V.K., et al., "Cytokines And Adhesion Molecules Contribute To The Ability of To Th					
	Maralin Broteolinid Protein-Specific I Cell Clottes to Wiedlate Emperature					
	Encephalomyelitis", J. Immunol. 151:4371-4382 (1993).					
	To the Committee of the A Committee of the Committee of t					
	* Kuchroo, V.K., et al., "Induction Of Experimental Allergic Encephalomyelitis By Myelin Proteolipid-Protein-Specific T Cell Clones and Synthetic Peptides", Pathobiology 59:305-312					
	* Kuchroo, V.K., et al., "T Cell Receptor (TCR) Usage Determines Disease Susceptibility In					
	* Kuchroo, V.K., et al., "I Cell Receptor (ICR) Gage Determined a Kuchroo, V.K., et al., "I Cell Receptor (ICR) Gage Determined Experimental Autoimmune Encephalomyelitis: Studies with TCR V Beta *.2 Transgenic					
	1					
	/ / / / / / / / / / / / _ / _ / _ / _ / _ / _ /					
	A = A = A = A = A = A = A = A = A = A =					
 						
	l m: 1 C if a Autoontigens: Indiction of Experimental Affolds Wilder					
	1 . \ ~ . \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \					
-	The state of Anti-gn 170 Monocional Alignous on CD (1997)					
	Binding By The Env Protein Of Human Immunodeliciency vitus Typo T, 30 to 10					
	62:3695-3702 (1988). * Liu, et al., "Molecular Mapping of a Pathogenically Relevant BP180 Epitope Associated * Liu, et al., "Molecular Mapping of a Pathogenically Relevant BP180 Epitope Associated					
	* Liu, et al., "Molecular Mapping of a Pathogenically Relevant By 166 – Fig. 11): 5449-5454 with Experimentally Induced Murine Bullous Pemphigoid" J. Immunol. 155 (11): 5449-5454					
·	(1995). * Lopez, et al., "Characterization of SPf(66)n: A Chimeric Molecule Used as a Malaria					
I	170,505,501 (1994)					
 	Tr' 1 Delle conocie' Decent Work Dil Hill Childina A dia 2					
	Luftig, et al., "Update on Viral Pathogenesis, Recent Work on The Viral Pathogenesis Research" ASM News, 56(7): 366-368, Illustrates the Paths Being Taken in Viral Pathogenesis Research" ASM News, 56(7): 366-368,					
1	1000					

U.S. Department of Commerce Patent and Trademark Office

Atty. Docket: 2002941-0053 In re Application No. 09/289,321

INFORMATION DISCLOSURE STATEMENT



Applicant: Baehovchin

Filing Date:

Group:

(Use several sheets if necessary) April 9, 1999 Group. 1653
 * Margnett, et al. "cDNA Cloning for Mouse Thyprocyte-Activating Molecule", A
Multifunctional Ecto-Dipeptidyl Peptidase IV (CD26) Included in a Subgroup of Serine Proteases", The Journal of Biological Chemistry, 267(4): 2200-2208, 1992.
 * Matteson, D., et al., "Synthesis And Properties Of Pinanediol a-Amido Boronic Esters"
 * Mittrucker, H.W., et al. "The Cytoplasmic Tail Of The T Cell Receptor Zeta Chain is
Required For Signaling Via CD26", Eur. J. Immunol., 25:295-297. (1995)
 * Morimoto, C., et al., 1F7 "A Novel Cell Surface Molecule, Involved in Helper Function Of CD4 cells". J. Immunol., 143:34030-3439 (1989) and published erratum appears in J. Immunology 144 (5):2027 (1990).
 * Mosmann, T.R., "Cytokine Patterns During The Progression To Aids", Science, 265:193-194, (1994).
 * Mullins, et al., "Transgenesis in the Rat and Larger Mammals" J. Clinical Investigation 96 (1): 30-37 (1996).
* Nardelli, et al., "A Chemically Defined Synthetic Vaccine Model for HIV-1", J. Immunol. 148 (3): 914-920 (1992).
* Nicola, N, et al., "Guidebook To Cytokines And Their Receptors", Sambrook and Tooze Publication, Pp. 1-257, (1994).
* O'Brien, et al., "An Immunogenetic Analysis of the T-Cell Recognition of the Major House Dust Mite Allergen Der p2: Identification of High- and Low-Responder HLA-DQ Alleles and Localization of T-Cell Epitopes" Immunology 86 (2):176-182 (1995).
* Panina-Bordignon, P., et al., "Universally Immunogenic T Cell Epitopes: Promiscuous Binding To Human MHC MHC Class II And Promiscuous Recognition By T Cells", Eur. J. Immunol. 19:2237-2242 (1989).
 * Ostresh, et al., "Generation and Use of Nonsupport-Bound Peptide and Peptidomimetic Combinatorial Libraries", Methods in Enzymology, 267: 220-234, 1996
* Perry, et al., "Autoreactive T Cell Specificity in Autoimmune Hemolytic Anemia of the NZB Mouse", Eur. J. Immunol. 26(1): 136-141 (1996).
* Perstorp Biotec Company, "Molecular Biology Catalog", (1994)
* Powers, C., et al., "Elastase Inhibitors For Treatment Of Emphysema - NHLBI Workshop Summary" US Dept. of Health and Human Services, 1097-1100, (1985).
* Protti, et al., "Myasthenia Gravis: Recognition of a Human Autoantigen at the Molecular Level" Immunol. Today 14 (7):363-368 (1993).
Reinhold, D., et al., "Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) induces secretion of transforming growth factor- 1 (TGF- 1) in stimulated mouse splenocytes and thymocytes" Immunology Letters, 58:29-35, (1997).
 * Reynolds, et al., "T and B Epitope Determination and Analysis of Multiple Antigenic By the Schisteres of Managine Programmental Vaccine Tripse-Phosphate Isomerase" J.

Peptides for the Schistosoma Mansoni Experimental Vaccine Triose-Phosphate Isomerase", J.

Immunol.152 (1):193-200 (1994).

U.S. Department of Commerce Patent and Tradema

Atty. Docket: 2002941-0053 In re Application No. 09/289,321

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant: Bachovchin

Filing Date: April 9, 1999

ORIGINALLY FILED Group: 1653

* Rini, J.M., et al., "Crystal Structure Of A Human Immunodeficiency Virus Type 1						
Neutralizing Antibody, 50.1, In Complex With Its V3 Loop Peptide Antigen", Proc. Natl.						
* Ritu, et al., "Construction of Synthetic Immunogens: Use of T- and B-Cell Epitopes of CS and RESA Proteins of Plasmodium Falciparum" Vaccine 10 (11): 761-765 (1992). * Schame S. et al. "Purified And Cell-Bound CD26: Enzymatic Inhibition, Antibody						
						Binding Profile, And Expression On T Cells In Relation To Other Surface Markers", Verh. K.
						Acad. Geneeskd. Belg., 56:537-559. (1994)
						Schmitz T., et al., "Potentiation Of The Immune Response In Hiv-1 + Individuals", J. Clin.
Invest., 97:1545-1549, (1996).						
* Schon, E., et al., "Dipeptidyl Peptidase IV in Human T Lymphoctyes. An Approach To The						
Role Of A Membrane Reptidase In The Immune System", Biomedica Biochimica Acta,						
45:1523-1528 (1986).						
* Schon, E., et al., "Dipeptidal Peptidase IV In The Immune System", Biol. Chem. Hoppe-						
Seyler, 372:305-311, (1991).						
* Schön, E., et al., "Dipeptidyl Peptidase IV In The Immune System. Effects of Specific						
Enzyme Inhibitors On The Activity Of Dipeptidyl Peptidase IV And Proliferation Of Human						
Lymphocytes", Biological Chemistry Hoppe Seyler 372:305-311 (1991).						
* Schon, E., et al., "The Dipeptidyl Peptidase IV, A Membrane Enzyme Involved In The						
Proliferation Lymphocytes", Biomedica Biochimica Acta, 44 (1985).						
* Schön, E., et al., "The Role Of Dipeptidyl Peptidase IV In Human T Lymphocyte						
Activation. Inhibitors And Antibodies Against Dipertidyl Peptidase IV Suppress Lymphocyte						
Proliferation And Immunoglobulin Synthesis In Vitro", Eur. J. Immunol. 17:1821-1826						
(1987). (1987). (1987). (1987). (1987). (1994).						
* Seed, B., "Making Agonists of Antagonists", Chemistry & Biology, 1:125-129 (1994). * Shimojo, et al., "Identification of the Disease-Related T Cell Epitope of Ovalbumin and						
Epitope-Targeted T Cell Inactivation in Egg Allergy" Int'l. Archives of Allergy & Immunol.						
* Snow, R.J., et al., "Studies On Proline Boronic Acid Dipeptide Inhibitors Of Dipeptidyl						
Peptidase IV: Identification Of A Cyclic Species Containing A B-N Bond", J. Am. Chem.						
Peptidase IV: Identification of A Cyclic Species Containing II 2 11, 2011 3 11 2011 4						
Soc., 116:10860-10869, (1994). * Songyang, Z., et al., "SH2 Domains Recognize Specific Phosphopeptide Sequences", Cell,						
* Subramanyam, M., et al., "CD26, AT-Cell Accessory Molecule Induction Of Antigen-						
Specific Immune-Suppression By Inactivation OF CD26: A Clue To The Aids Paraxox?", in						
Dipeptidyl Peptidase IV (CD26) in Metabolism and Immune Response, Ed. B. Fleischer: 155-						
162, (1995)						
* Subramanyam, M., et al., "Mechanism Of Hiv-1 Tat Induced Inhibition Of Antigen-Specific						
T Cell Responsiveness", J. Immunol., 150:2544-2553, (1993)						
Subramanyam, W.G., et al., "Mechanism of HIV-1 Tat Induced Inhibition Of Antigen-						
Specific T Cell Responsiveness", J. Immunol. 150:2544-2553 (1993).						

U.S. Department of Commerce Patent and Trademark Office Atty. Docket: 2002941-0053

In re Application No. 09/289,321

INFORMATION DISCLOSURE STATEMENT

e several sheets if necessary)

Applicant: Bachovchin

FEB 2 0

Filing Date:

GroupTECH CENTER 1603/20

(Use seve	ral sheets if necessary)	CATENT & TRADE	April 9, 1999	1653 1653
	12/38 (1004)	propro Determined By	Nmr Spectroscopy",	Biochemistry, 33.12427-
	* Tam, J.P., "Synthetic I Density Multiple Antige (1988).	enic Peptide System",	Proc. Natl. Acad. Sci.	. USA, 85 :3409-3413,
	CD26" I Jamunol 14	0 ·481-486 (1992)		Cell Activation Antigen
	* Tanaka, T., et al. "Clo CD26", J. Immunol. 149	oning And Functional 9: 481-486 (1992); pu	blished erratum appe	*
	* Tanaka, T., et al., "Th	ic Activity" <i>Proc. Na</i>	tl. Acad. Sci. USA, 90	tigen Requires Dipeptidyl 1:4586-4590. (1993)
	* Thompson, R., "Use (Of Peptide Aldehydes 12:1:47-51 (1973).	To Generate Transition	on-State Analogs Of
	Thompson, R. "Peptide	Aldehydes: Potent In	\	Cysteine Proteases", 19:
	* Uibo, et al., "Characte with Autoimmune Poly	erization of Adrenal A glandular Syndrome (utoentigens Recogniz APS) Type I. (J. Auto	zed by Sera From Patients pimmunity 7 (3): 399-411
	* Van Noort, et al., "The Autoantigen in Multiple	ne Small Heat-Shock F	Protein Alpha B-Crys	tallin as Candidate 2995).
	* Watson I.D., "Contin	nuous Proliferation Of	Murine Antigen Spe	cific Helper T Lymphocytes
	in Culture", J. Experim * Welch, J.T., and Lin Dipeptidyl Peptidase I	J. /Fluoroolefin Cont	aining Dipetide Isogei	res As Inhibitors Of
	* Wijdenes, et al., "Mo Use the gp130 For Sign	noclonal Antibodies (mAb) Against gp130	Imitating Cytokines Which
	* Wyss-Coray, T., et al To T Cells: Evidence	l., "Use Of Antibody/I For T Cells Processing	Peptides Constructs C 3 And Presentation",	Of Direct Antigenic Peptides Cellular Immunol., 139
	* Yoshimoto, T., et al., Derivates On Prolyl	, "Comparison Of Inhi	bitory Effects Of Pro 98:975-979, (1985)	linal-Containing peptide
	* Zhu, X., et al., "T Ce Artemisiifolia (Amb a	ell Epitope Mapping of 5) and Ambrosia Triff	f Ragweed Pollen All ida (Amb t 5) and the 155 (10):5064-5073 ((1995).
	* Zimmerman, D.H., e	et al. "A New Approace of Activating T Cells".	h To T-Cell Activation Naccine Res., 5:91-1	on: Natural And Symmetic 102, (1996).
	Zimmerman, D.H., et a	al., "Immunication Wi	th Peptide Heterocon	jugates Primes A T Helper

U.S. Department of Commerce Patent and Trademark Office Atty. Docket: 2002941-0053

In re Application No. 09/289,321

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

FEB 13 200 FEB

Applicant: Bachovchin

Filing Date: April 9, 1999 Group: 1653

EXAMENER

NOT

Considerell

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

3184391_1.DOC

COPY OF PAPERS ORIGINALLY FILED

RECEIVED

FEB 2 0 2000

TECH CENTER 1600/2000